Robinson Byron 4
4 · Janux Therapeutics, Inc. · Filed Mar 3, 2022
Insider Transaction Report
Form 4
Robinson Byron
Chief Strategy Officer
Transactions
- Award
Stock Option (right to buy)
2022-03-01+230,000→ 230,000 totalExercise: $16.81Exp: 2032-02-29→ Common Stock (230,000 underlying)
Footnotes (1)
- [F1]25% of the shares subject to the option vest on February 28, 2023 and the balance will vest in equal monthly installments thereafter over a three year period.